A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population.
Action Potentials
Adolescent
Adrenergic Antagonists
/ therapeutic use
Adult
Aged
Aged, 80 and over
Anti-Arrhythmia Agents
/ therapeutic use
Anticoagulants
/ therapeutic use
Atrial Fibrillation
/ drug therapy
Bronchodilator Agents
/ therapeutic use
Cause of Death
Child
Child, Preschool
Comorbidity
Data Warehousing
Digoxin
/ therapeutic use
Female
Heart Conduction System
/ physiopathology
Heart Rate
Humans
Infant
Infant, Newborn
Lung
/ physiopathology
Male
Middle Aged
Prospective Studies
Protective Factors
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Risk Assessment
Risk Factors
Spain
/ epidemiology
Time Factors
Treatment Outcome
Young Adult
CHA2DS2-VASc
COPD
atrial fibrillation
big data
stroke
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
Historique:
entrez:
14
3
2019
pubmed:
14
3
2019
medline:
30
7
2019
Statut:
epublish
Résumé
Patients with COPD are at higher risk of presenting with atrial fibrillation (AF). Information about clinical outcomes and optimal medical treatment of AF in the setting of COPD remains missing. We aimed to describe the prevalence of COPD in a sizeable cohort of real-world AF patients belonging to the same healthcare area and to examine the relationship between comorbid COPD and AF prognosis. Prospective analysis performed in a specific healthcare area. Data were obtained from several sources within the "data warehouse of the Galician Healthcare Service" using multiple analytical tools. Statistical analyses were completed using SPSS 19 and STATA 14.0. A total of 7,990 (2.08%) patients with AF were registered throughout 2013 in our healthcare area (n=348,985). Mean age was 76.83±10.51 years and 937 (11.7%) presented with COPD. COPD patients had a higher mean CHA AF patients with COPD have a higher incidence of adverse events with significantly increased rates of all-cause mortality and hemorrhagic events than AF patients without COPD. However, comorbid COPD was not associated with differences in cardiovascular death or stroke rate. OA and beta-blocker treatment presented a risk reduction in mortality while digoxin use exerted a neutral effect.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with COPD are at higher risk of presenting with atrial fibrillation (AF). Information about clinical outcomes and optimal medical treatment of AF in the setting of COPD remains missing. We aimed to describe the prevalence of COPD in a sizeable cohort of real-world AF patients belonging to the same healthcare area and to examine the relationship between comorbid COPD and AF prognosis.
METHODS
METHODS
Prospective analysis performed in a specific healthcare area. Data were obtained from several sources within the "data warehouse of the Galician Healthcare Service" using multiple analytical tools. Statistical analyses were completed using SPSS 19 and STATA 14.0.
RESULTS
RESULTS
A total of 7,990 (2.08%) patients with AF were registered throughout 2013 in our healthcare area (n=348,985). Mean age was 76.83±10.51 years and 937 (11.7%) presented with COPD. COPD patients had a higher mean CHA
CONCLUSION
CONCLUSIONS
AF patients with COPD have a higher incidence of adverse events with significantly increased rates of all-cause mortality and hemorrhagic events than AF patients without COPD. However, comorbid COPD was not associated with differences in cardiovascular death or stroke rate. OA and beta-blocker treatment presented a risk reduction in mortality while digoxin use exerted a neutral effect.
Identifiants
pubmed: 30863038
doi: 10.2147/COPD.S174443
pii: copd-14-371
pmc: PMC6388772
doi:
Substances chimiques
Adrenergic Antagonists
0
Anti-Arrhythmia Agents
0
Anticoagulants
0
Bronchodilator Agents
0
Digoxin
73K4184T59
Types de publication
Journal Article
Multicenter Study
Langues
eng
Pagination
371-380Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Circulation. 2003 Jun 17;107(23):2920-5
pubmed: 12771006
Eur Respir J. 2003 Jul;22(1):1-2
pubmed: 12882441
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003566
pubmed: 16235327
Chest. 2005 Oct;128(4):2068-75
pubmed: 16236856
Am J Physiol. 1992 Jan;262(1 Pt 2):H47-55
pubmed: 1733321
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
Biochem Pharmacol. 2008 Oct 1;76(7):841-9
pubmed: 18692028
Circ J. 2010 Sep;74(9):1815-21
pubmed: 20631454
Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1147-53
pubmed: 20724528
Eur Heart J. 2010 Oct;31(19):2369-429
pubmed: 20802247
JAMA. 2011 May 25;305(20):2080-7
pubmed: 21610240
Int J Chron Obstruct Pulmon Dis. 2012;7:457-94
pubmed: 22927753
Int J Cardiol. 2013 Oct 3;168(3):2940-1
pubmed: 23632115
Chest. 2013 Jul;144(1):266-273
pubmed: 23880677
Europace. 2014 Feb;16(2):182-8
pubmed: 23960091
Circulation. 2014 Dec 2;130(23):e199-267
pubmed: 24682347
Am J Cardiol. 2014 Jul 15;114(2):272-7
pubmed: 24878126
J Am Med Dir Assoc. 2014 Aug;15(8):576-81
pubmed: 24894999
Exp Ther Med. 2014 Dec;8(6):1677-1682
pubmed: 25371714
Circ J. 2015;79(3):495-502
pubmed: 25746525
Eur Respir J. 2015 Apr;45(4):879-905
pubmed: 25829431
Lancet Respir Med. 2015 Aug;3(8):631-9
pubmed: 26208998
J Saudi Heart Assoc. 2016 Jan;28(1):15-21
pubmed: 26778901
Acta Cardiol Sin. 2015 Jul;31(4):325-36
pubmed: 27122889
Int J Cardiol. 2016 Sep 1;218:298-304
pubmed: 27240155
Eur J Intern Med. 2017 Jan;37:75-82
pubmed: 27727075
Intern Med J. 2016 Nov;46(11):1336-1340
pubmed: 27813357
Am Heart J. 2016 Nov;181:83-91
pubmed: 27823697
J Cardiol. 2017 May;69(5):699-705
pubmed: 28188041
Arch Bronconeumol. 2017 Mar;53(3):128-149
pubmed: 28274597
Circulation. 1998 Sep 8;98(10):946-52
pubmed: 9737513
J Clin Gastroenterol. 1998;27 Suppl 1:S80-6
pubmed: 9872502